Alnylam Pharmaceuticals
ALNY
#564
Rank
HK$345.37 B
Marketcap
HK$2,604
Share price
0.51%
Change (1 day)
41.23%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024: -HK$1.85 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are HK$3.21 Billion. In 2024 the company made an earning of -HK$1.85 Billion, an increase over its 2023 earnings that were of -HK$2.45 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024-HK$1.85 Billion-24.59%
2023-HK$2.45 Billion-67.84%
2022-HK$7.6 Billion36.93%
2021-HK$5.55 Billion-8.04%
2020-HK$6.04 Billion-15.66%
2019-HK$7.16 Billion12.23%
2018-HK$6.38 Billion62.91%
2017-HK$3.92 Billion17.78%
2016-HK$3.33 Billion43.44%
2015-HK$2.32 Billion60.69%
2014-HK$1.45 Billion98.2%
2013-HK$0.73 Billion
2011-HK$0.43 Billion27.48%
2010-HK$0.34 Billion-10.92%
2009-HK$0.38 Billion95.77%
2008-HK$0.2 Billion
2006-HK$0.31 Billion-9.13%
2005-HK$0.35 Billion34.74%
2004-HK$0.26 Billion36.79%
2003-HK$0.19 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
HK$127.91 B 12,447.77%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$71.18 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
HK$40.91 B 3,913.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-HK$1.98 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-HK$0.38 Billion-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-HK$1.25 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$16.83 B 1,551.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
HK$1.10 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA